Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) announced that it has filed its Quarterly Report on Form 10-Q for its second quarter fiscal year (FY) 2014 ended October 31, 2013. In connection with that filing, the company is providing a review of recent achievements and an update on business operations and future milestones. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) stock opened at $4.99 in last trading session, and closed at $4.50, trading in the range of $4.50 – $4.99. The stock showed a negative weekly performance of -7.41%.
Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of cancer immunotherapies, announced that it is one of 54 companies approved to share the $60 million allocation through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2014. Each of the 54 selected companies is expected to receive approximately $1.1 million which is a 21% increase from last year. Advaxis, Inc. (NASDAQ:ADXS) shares closed at $4.24 on last trade day, by decreasing -5.36%. Stock 52 week range is $2.60 – $19.38. Company’s market capitalization is $53.63 billion.
Enzymotec Ltd (NASDAQ:ENZY) was downgraded by analysts at Merrill Lynch to an “underperform” rating in a research report issued to clients and investors on Wednesday, StockRatingsNetwork reports. Enzymotec Ltd (NASDAQ:ENZY) stock fell -6.54% and finished the last session at $27.01. The EPS of the stock remained 0.45. Company’s market capitalization is $581.57 billion.
Genetic Technologies Limited (ADR) (NASDAQ:GENE) said that it has issued a $5 million redeemable convertible note to Ironridge BioPharma, a division of institutional investor Ironridge Global IV, Ltd. Genetic Technologies Limited (ADR) (NASDAQ:GENE) stock opened at $1.48 in last trading session and closed at $1.43. The 52 week range of the stock is $1.35 – 3.35 and the day range was $1.41 – $1.49.